$6.29
0.274.49%
Last update: Oct 27, 6:29 PM
Myriad Genetics Inc (MYGN) Stock Price, Quote, News & History
MYGNNASDAQ
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
You can purchase shares of Myriad Genetics (NASDAQ:MYGN) through any online brokerage.
Other companies in Myriad Genetics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Myriad Genetics has a consensus price target of $10.43.
The stock price for Myriad Genetics (NASDAQ: MYGN) is $6.3158 last updated October 27, 2026 at 6:29 PM EDT.
There are no upcoming dividends for Myriad Genetics.
Myriad Genetics does not have any upcoming earnings scheduled.
There is no upcoming split for Myriad Genetics.
Myriad Genetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its...
